José Antonio Cornejo-Guerra, MD, MSc, FACC

After 8 years of research and treatment of acute coronary syndromes, the natural next step is to advocate for a bill to prevent and treat acute myocardial infarction. It was presented yesterday in Congress. #GlobalHealth #Advocacy @ACCinTouch @gt_acs

Mañana es el turno de Guatemala de participar con Abordaje de CIA. 17pm hora Gt.

Thank you to ACC.26 ( @ACCinTouch ) for the opportunity to present a complex structural case from @HospigenGT At New Orleans

Great to see you all! 👋 Continuing our ACHD (Adult Congenital Heart Disease) education series – a must-know for all of us in cardiology. #ACHD #AdultCongenitalHeartDisease #StructuralCardiology #CardiologyEducation #InterventionalCardiology @ACCinTouch

@Bravo__MD @jacorne5 @carlapatprachd @Juanma_Munoz29 @Becerra_MD I am sorry to not see you!

Join us tomorrow! 6pm Guatemalan time. @MayoClinicCV @ISACHD @IncichR @HospigenGT

First day of the Structural Heart Innovation session in Bogotá by @meril, alongside dear friends and colleagues!

Successful percutaneous closure of a giant PDA in a postpartum woman battling severe pulmonary hypertension. Leave no patient without understanding their disease—tailored assessment reverses “inoperable” labels, even in LMICs. Trial occlusion needed. #StructuralHeart

2025 Ja's Cardiology Recap linkedin.com/posts/jos%C3%A…

🫀📉 LDL-C management made simple: lower for longer really is better This 2025 National Lipid Association (NLA) guidance delivers a clear, unified message across complex and sometimes conflicting guidelines: LDL cholesterol is causal for ASCVD, and sustained lowering over time saves lives . 🧠 Why this document matters Despite decades of evidence, LDL-C measurement and control remain suboptimal, even in patients with established ASCVD. Meanwhile, cardiovascular mortality—especially in younger and middle-aged adults—is rising again. This guidance aims to cut through complexity and offer practical, patient-centered clarity for everyday care. 📌 Core principles (no ambiguity) LDL-C is the building block of atherosclerotic plaque ASCVD risk falls linearly and proportionally with LDL-C reduction Benefit depends on how low you go and how long you stay there👉 Hence the key message: lower for longer is better 📊 Screening & targets All adults: lipid panel at least every 5 years High-risk patients or on therapy: more frequent monitoring LDL-C <100 mg/dL for general prevention Much lower targets for high and very-high-risk patients Evidence supports safety of LDL-C levels down to 10–30 mg/dL ✅ 💊 Therapy: stepwise but decisive Statins remain first-line If targets aren’t reached → add non-statins (ezetimibe, PCSK9 inhibitors, bempedoic acid, etc.) Combination therapy beats statin dose escalation Statin intolerance is real—but manageable with alternatives 🥗 Lifestyle still matters Diet, exercise, sleep, smoking cessation, and stress control are framed not as optional extras, but as foundational LDL-lowering tools. 🔮 The real takeaway ASCVD is a lifetime exposure disease. Waiting until risk is “high enough” is a missed opportunity. Early identification, sustained LDL-C control, and team-based care—often involving lipid specialists—are key to bending the curve. 🚀 Bottom line LDL-C management doesn’t need to be complicated. Measure it. Treat it. Maintain it. Lower. For longer. Better.

PCR GLOBAL INTERVENTIONAL ACADEMY, First Edition starting in India with massive involvement of the attendees 👏🏽👏🏽👏🏽 @PedroLemosMD @PCRonline Ole De Backer Andreas Baumbach

Glad to be part of the first cohort of @PCRonline Global Interventional Academy Alumni. Our initial meeting in India was an invaluable opportunity to share experiences with colleagues and learn directly from the faculty leading the course. See you in Brazil!

Great educational meeting at PCR London Valves 2025 @PCRonline —bringing science to life with expert insights and detailed explanations!

Convocatoria abierta para asistente de investigación. Manda tu CV a soniamoreno2804@gmail.com. Fecha límite: 17 de octubre de 2025.

Great session in Guatemala on reperfusion as part of the Guatemalan Cardiology Congress. Dedicated faculty from across the region, stretching from Canada to Peru, shared their experiences and strategies to overcome barriers. This movement must become a nationwide effort!

On August 26th, the ACS-GT team had the honor of presenting, on behalf of the Aldo Castañeda Foundation, our flatboard poster on the feasibility of percutaneous PDA closure through a public-private partnership in a LMIC. 🔗 You can explore our full work by scanning the QR code!

CathLab + EchoLab: Heart Team San Juan de Dios! Guatemala 🇬🇹

Mitral valvuloplasty with a 28mm Inoue balloon in Lutembacher syndrome at San Juan de Dios CathLab, Guatemala. Rheumatic mitral valve stenosis (0.8 cm²) was progressively dilated to 1.4 cm² (from 1.03 cm²/m²). Excellent images by @pablogonzalezmd @HospigenGT #structuralHeart

More projects are underway, with submissions under review at JACC Case Reports and Global Heart. These efforts strengthened our multidisciplinary cath-lab team and we’re excited, and committed, to advancing cardiovascular research in Guatemala. (3/3)

5 abstracts were accepted. 2 new publications in JACC journals; 1 to be published after the ACC Latin America conference; and 1 in Journal of Pediatric Cardiology. 3 Poster presentations at international meetings (ACC 2025, soon PICS and Latin America ACC 2025) (2/3)

A year ago, Sonia Moreno, MD, joined ACS-GT. Since then, she has recollected data of ACS, CRS, AAS, CHD (Including an international one, GHATI ACC) that powered multiple abstracts/papers and international posters (1/3)